“Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.”
— Warren Buffett
A long holding period can reveal far more about a stock than short-term price swings. For Regeneron Pharmaceuticals, Inc. (NASD: REGN), a $10,000 investment made in September 2016 grew to $19,412.11 by September 16, 2026, assuming dividends were reinvested. That translates to a total return of 94.07% and an annualized return of 6.86% over the 10-year span.
The result is solid, though not explosive. It illustrates an important point about long-term stock returns: even for a well-known biotechnology company, the investment outcome depends not only on business performance, but also on the valuation paid at the starting point and the extent to which shareholder returns come from price appreciation versus cash distributions.
REGN 10-Year Return Details
| Start date: | 09/19/2016 |
|
|||
| End date: | 09/16/2026 | ||||
| Start price/share: | $402.83 | ||||
| End price/share: | $774.61 | ||||
| Starting shares: | 24.82 | ||||
| Ending shares: | 25.05 | ||||
| Dividends reinvested/share: | $6.34 | ||||
| Total return: | 94.07% | ||||
| Average annual return: | 6.86% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $19,412.11 | ||||
Put simply, every $10,000 invested in REGN on 09/19/2016 would be worth $19,412.11 on 09/16/2026 under a dividend-reinvestment assumption. On a total return basis, the holding nearly doubled over the period. These figures were computed with the Dividend Channel DRIP Returns Calculator.
What Drove The 10-Year Return
The bulk of the gain came from share-price appreciation rather than income. REGN rose from $402.83 to $774.61 over the period, while total dividends reinvested amounted to $6.34 per share. That profile is typical of many biotechnology stocks, where shareholder returns are often driven primarily by product performance, pipeline expectations, margins, and valuation rerating rather than by a high cash yield.
The difference between starting shares and ending shares also underscores the limited role of income in this case. An initial 24.82 shares grew to 25.05 shares after a decade of reinvestment, indicating that dividends added only a modest number of incremental shares. In other words, REGN’s 10-year total return was overwhelmingly an equity appreciation story.
Dividend Contribution And Yield On Cost
Dividends still matter because total return includes every source of shareholder value. Over the period measured above, Regeneron Pharmaceuticals, Inc. paid $6.34 per share in dividends that were assumed to be reinvested on the ex-dividend date using the closing price. That is the standard framework used in many total-return calculations because it captures the compounding effect of reinvestment.
Based on the most recent annualized dividend rate of $3.76 per share, REGN has an indicated current yield of approximately 0.49%. Using the original purchase price of $402.83 per share, that implies a yield on cost of roughly 0.93%.
Key Takeaways From This REGN Investment
For quick reference, the 10-year REGN investment case can be summarized as follows:
- $10,000 invested in REGN in September 2016 grew to $19,412.11 by September 2026.
- Total return was 94.07%.
- Annualized return was 6.86%.
- Most of the return came from stock-price appreciation, not dividends.
- The current indicated dividend yield remains relatively low at about 0.49%.
How To Interpret The Result
A near-doubling over 10 years is a respectable outcome, but annualized performance matters more than the headline ending value. A 6.86% compound annual return is materially different from the impression created by a 94.07% cumulative gain. That distinction is especially important when comparing REGN with alternatives such as broad equity indexes, other large-cap biopharma names, or income-oriented strategies.
This also highlights the importance of entry price. Even strong businesses can generate only moderate long-term stock returns if purchased at elevated valuations, while more modest businesses can occasionally produce better equity returns if bought at sufficiently attractive prices. In a sector like biotechnology, where sentiment around drug portfolios and future revenue streams can shift materially over time, valuation discipline often has an outsized effect on realized returns.
One final observation: for a low-yield stock, dividend reinvestment has a relatively small impact on the final value compared with what it would mean for a higher-yielding company. That does not diminish the usefulness of total-return analysis; it simply clarifies that REGN has functioned primarily as a capital appreciation investment over this period rather than an income vehicle.
“Twenty years in this business convinces me that any normal person using the customary three percent of the brain can pick stocks just as well, if not better, than the average Wall Street expert.” — Peter Lynch
